INTRODUCTION {#s1}
============

The survival rate of patients with metastatic renal cell carcinoma has improved remarkably since the introduction of molecular targeted drugs \[[@R1]--[@R4]\]. We classified the prognoses of patients with metastatic renal cell carcinoma (mRCC) and used the classification as an index in selecting a treatment approach. The Memorial Sloan Kettering Cancer Center (MSKCC) risk classification is a survival risk classification advocated by Motzer et al. \[[@R5]\] before treatment using molecular targeted drugs became common. This classification is reportedly associated with prognosis even in the era of molecular targeted drugs \[[@R6]\] and is still widely used. However, the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk classification advocated by Heng et al. \[[@R7]\] was established in the era of molecular targeted drugs and is also used as widely as the MSKCC risk classification. There is also another risk classification targeted for Japanese patients, which was remodeled to be used more practically by incorporating factors attributable to metastatic organs \[[@R8]\].

However, patients in the intermediate group accounted for about half of all the patients. Moreover, the intermediate-risk group involves 1 or 2 risk factors; thus, there is a great variability among the patients. Consequently, it has not been decided whether it is appropriate to treat the intermediate-risk group as one group. Sella et al. based on six clinical trials data consisting in well-selected patients treated with sunitinib only, reported the heterogeneity of patients identified as having intermediate risk using the MSKCC risk criteria \[[@R9]\].

In this study, therefore, we performed a retrospective analysis of patients treated with tyrosine kinase inhibitors and mammalian target of rapamycin inhibitor in the intermediate-risk group within a real-world Japanese population to investigate the necessity of stratifying patients in the intermediate-risk group. Optimal classification for Japanese population may predict treatment effect or investigate a treatment approach in the future.

RESULTS {#s2}
=======

Table [1](#T1){ref-type="table"} shows the characteristics of the study population. Patients in the intermediate risk class accounted for about 50% of all risk classes. The median overall survival (OS) was 41.2 months ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). The median OS of the favorable-, intermediate-, and poor-risk groups based on the MSKCC criteria were 91.0, 33.6, and 15.2 months, respectively ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). Patients in the favorable-risk group had a significantly prolonged survival than those in the other groups (hazard ratio (HR) 0.22, 95% confidence interval (CI) 0.11-0.44, p\<0.001). Conversely, patients in the poor-risk group had a significantly shorter survival time compared to those in the other groups (HR 3.04, 95% CI 1.95-4.74, p\<0.001) and compared to those in the intermediate-risk group alone (HR 2.15, 95% CI 1.37-3.39). The median OS using the first-line treatments- sunitinib, sorafenib, and temsirolimus were 69.6, 33.6, and 11.8 months, respectively.

###### Patients characteristics and treatments (N=234)

  ----------------------------- -------------- -------------------- -------------- ----
  Age (years), median                          67                   range: 35-84   
                                               Number of patients                  
  Sex                           Male           180                                 
                                Female         54                                  
  MSKCC                         Favorable      50                   21.4           \%
                                Intermediate   126                  53.8           \%
                                Poor           49                   20.9           \%
                                unknown        9                    3.8            \%
  Number of metastatic organs   Single         118                  50.4           \%
                                Multiple       116                  49.6           \%
  Sites of metastasis           Lung           153                                 
                                Lymph node     59                                  
                                Bone           67                                  
                                Pancreas       14                                  
                                Liver          20                                  
                                Brain          13                                  
  Prior nephrectomy             Yes            219                  93.6           \%
                                No             15                   6.4            \%
  Molecular targeted agents                                                        
  1st-line                      Sunitinib      137                                 
                                Sorafenib      75                                  
                                Pazopanib      10                                  
                                Temsirolimus   12                                  
  2nd-line                      Everolimus     32                                  
                                Axitinib       57                                  
                                Sunitinib      25                                  
                                Temsirolimus   11                                  
                                Pazopanib      2                                   
                                Nivolumab      5                                   
                                Sorafenib      5                                   
  3rd-line                      Everolimus     18                                  
                                Sunitinib      14                                  
                                Axitinib       16                                  
                                Sorafenib      11                                  
                                Temsirolimus   11                                  
                                Nivolumab      9                                   
                                Pazopanib      4                                   
  ----------------------------- -------------- -------------------- -------------- ----

Table [2](#T2){ref-type="table"} shows the characteristics of patients in the intermediate-risk class. Patient characteristics were similar between the two subgroups. Increased positivity for risk factors of the MSKCC classification between Int-1 and Int-2 groups were for performance status and serum hemoglobin level. The median OS using the first-line treatments- sunitinib and sorafenib were 43.4 and 30.7 months, respectively, in the intermediate risk group (log-rank test, p=0.103). The progression-free survival (PFS) and OS of the Int-1 group were significantly higher than those of the Int-2 group (Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). Patients in the Int-1 group had a significantly shorter survival than those in the favorable group (HR 2.88, 95% CI 1.32-6.30, p=0.007). No significant difference in survival was found between the Int-2 and poor-risk groups (HR 1.42, CI 0.87-2.29, p=0.151). The median OS using the first-line drugs- sunitinib and sorafenib were 44.1 and 43.6 months, respectively, in the Int-1 group, (log-rank test, p=0.438) and were 27.2 and 15.2 months, respectively, in the Int-2 group, (log-rank test, p=0.099). We evaluated the risk factors of the MSKCC criteria to determine the risk factors that affect survival rate between the two groups, but no significant difference was observed in any of the risk factors (performance status (PS), 0 vs ≥1, HR 0.62, 95% CI 0.35-1.08; serum hemoglobin level, \< lower limit of normal (LLN) vs ≥LLN, HR 1.41, 95% CI 0.82-2.43; time from diagnosis to treatment, \<1 year vs ≥1 year, HR 1.47, 95% CI 0.85-2.52; corrected calcium level, \<10 mg/dL vs ≥10 mg/dL, HR 0.40, 95% CI 0.15-1.08; lactate dehydrogenase (LDH) level, \<1.5x upper limit of normal (ULN) vs 1.5xULN, HR 0.98, 95% CI 0.39-2.48).

###### Patients characteristics and treatments in intermediate group (N=126)

                                                                                                               Intermediate 1       Intermediate 2                        
  ------------------------------------------------------------------------- ---------------------------------- -------------------- ---------------- -------------------- --------------
  Age (years), median                                                                                          67                   range: 40-80     69                   range: 39-83
                                                                                                               Number of patients                    Number of patients   
  Sex                                                                       Male                               53                                    46                   
                                                                            Female                             11                                    16                   
  Number of metastatic organs                                               Single                             39                                    36                   
                                                                            Multiple                           25                                    26                   
  Sites of metastasis                                                       Lung                               46                                    45                   
                                                                            Lymph node                         12                                    16                   
                                                                            Bone                               18                                    15                   
                                                                            Pancreas                           4                                     2                    
                                                                            Liver                              3                                     4                    
                                                                            Brain                              2                                     2                    
  Positive factors in the Memorial Sloan Kettering Cancer Center criteria   Performance status                 8                                     35                   
                                                                            Serum hemoglobin level             16                                    36                   
                                                                            Time from diagnosis to treatment   33                                    40                   
                                                                            Corrected calcium level            4                                     6                    
                                                                            Lactate dehydrogenase level        3                                     7                    
  1st-line treatment                                                        Sunitinib                          38                                    39                   
                                                                            Sorafenib                          23                                    16                   
                                                                            Pazopanib                          2                                     3                    
                                                                            Temsirolimus                       1                                     4                    
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Fifty-six out of the 126 patients in the intermediate group died. Cox proportional stepwise multivariate analysis showed that the Int-1 and Int-2 classification was an independent risk factor for OS (HR 1.91, 95% CI 1.11-3.30, p=0.019). (Table [3](#T3){ref-type="table"})

###### Results of the Cox proportional stepwise multivariate analysis for the association between the variables and overall survival

  Comparison                          Overall survival (months), median   Unadjusted                         Adjusted                                                                    
  ----------------------------------- ----------------------------------- ---------------------------------- ---------- ---- ------------- ------------------ ------- ------------------ -------
  Metastasis in a single organ        vs                                  Metastasis in multiple organs      38.8       vs   30.7          1.27 (0.74-2.18)   0.381   1.38 (0.80-2.38)   0.239
  Int-1                               vs                                  Int-2                              43.6       vs   22.5          1.93 (1.12-3.33)   0.017   1.91 (1.11-3.30)   0.019
  Presence of pancreatic metastasis   vs                                  Absence of pancreatic metastasis   32.6       vs   not reached   0.19 (0.02-1.40)   0.103   0.18 (0.02-1.38)   0.100

Abbreviations: HR, hazard ratio; CI, confidence interval.

DISCUSSION {#s3}
==========

To the best of knowledge, we reported here for the first time an investigation of the necessity of stratifying patients in the intermediate-risk group of the MSKCC risk classification within a real-world Japanese population. We demonstrated that there was a significant difference in the survival period between Int-1 and Int-2 groups of the intermediate-risk group. This finding suggests that we need to subcategorize the intermediate-risk group to predict treatment effect or investigate a treatment approach in the future.

In addition to other studies, we previously reported that patients in the intermediate-risk group account for about 50% of patients with metastatic renal carcinoma and their survival rate falls between those of the favorable- and poor-risk groups \[[@R8], [@R10], [@R11]\]. However, a subcategorization of the intermediate-risk group has not been considered. In recent years, however, clinical trials have been conducted within the intermediate- and poor-risk groups alone or occasionally, clinical trials have been conducted to prove efficacy within these groups alone \[[@R12], [@R13]\]. Accordingly, a need has arisen to change the treatment approach to match the individual risk groups. However, since the intermediate-risk group involves 1 or 2 risk factors, there is a great variability among the patients and consequently, it has not been decided whether it is appropriate to treat the intermediate-risk group as one group. In our analysis, the OS of the Int-1 and Int-2 groups were 43.6 and 22.5 months, respectively, indicating that the prognosis of the latter group was significantly poorer (log-rank test, p=0.017). The most common positive risk factor in both groups was PS, followed by anemia. This finding suggests that the aggravation of PS and anemia may possibly have an influence on prognosis in both groups. Sella et al. \[[@R9]\] reported that they found a difference in OS and PFS between the Int-1 and Int-2 groups and in PFS and the objective response rate among patients with Eastern Cooperative Oncology Group PS ≥1. These analyses were compiled from the results of six clinical trials, and a conclusion was reached that segmenting the intermediate-risk group and stratification by PS are necessary. Our real-world data supports this conclusion. In addition, the mean survivals in the favorable- and poor-risk groups in the MSKCC study were 91.0 and 15.2 months, respectively. Since the difference in these groups was greater than that in the Int-1 group, prognosis prediction and treatment approach should be treated in a separate study group.

We showed in our previous study that the presence or absence of pancreatic metastasis and the number of metastatic organs, as well as the MSKCC classification, had an influence on prognosis \[[@R10]\]. However, Shinohara et al. \[[@R8]\] advocated a risk classification designed for Japanese patients. They defined the following four items as the stratification factors: hemoglobin; less than 1 year from diagnosis to treatment; LDH; and liver, bone, or multiple organs metastases. Consequently, they classified the favorable-risk group as 0-1 factor positive; the intermediate-risk group as 2 factors positive; and the poor-risk group as ≥3 factors positive. Compared to the MSKCC risk classification, this classification additionally incorporated the metastatic organs or the number of metastatic organs as stratification factors, but it was reported that its correlation with life prognosis was as favorable as that of the MSKCC risk classification. In a multivariate analysis to assess the number of metastatic organs, however, it was revealed that the number of metastatic organs was not an independent factor that could affect the survival period of patients in the Int-1 and Int-2 groups. This finding suggests that the number of positive risk factors is more important than the number of metastatic organs in the intermediate-risk group.

In the present study, OS was 41.2 months, which is longer than that in large-scale clinical trials \[[@R14], [@R15]\]. This may be influenced by the longer life expectancy of Japanese compared to other races. Furthermore, this may be due to the fact that Japanese have good treatment outcomes including other carcinomas \[[@R16]\]. However, Motzer et al. \[[@R17]\] reported that there were no differences in PFS or OS in Caucasian vs Asian patients. Conversely, there were significant differences in PFS and OS in Caucasians vs non-Caucasians, non-Asian patients. Several investigators also showed that the survival period after the introduction of molecular targeted drugs seemed prolonged compared to that before their introduction \[[@R1], [@R3], [@R4]\]. Of the first-line treatment drugs, the survival period of the patients who used sunitinib was the longest. The survival period of patients who used temsirolimus was remarkably short, probably due to its use in the poor-risk group.

There were some limitations to this study; we conducted a retrospective study and the treatment drugs were not unified. Most of the patients in this study were enrolled at a time before the introduction of immuno-oncology drugs in the clinical management of mRCC patients; thus, the survival period may prolong if immuno-oncology drugs become more widely used in the future \[[@R13], [@R18], [@R19]\]. In particular, treatment results of immuno-oncology drugs among patients in the poor-risk group are much awaited. Another limitation is that we reported here the necessity of stratifying patients in the intermediate-risk group using the MSKCC criteria. The IMDC criteria, which is another risk classification, is now often adapted to mRCC patients. However, some of our study participants had no available data regarding neutrophil counts, especially those who were diagnosed before 2013; hence, we did not investigate the IMDC risk. Although the MSKCC criteria was established in the cytokine therapy era, we have in addition to other authors, showed that it can be applied efficiently to Japanese patients, even in the era of molecular targeted drugs \[[@R8], [@R10]\].

In conclusion, we found that patients in the intermediate-risk group based on the MSKCC risk classification had different prognoses, depending on the number of positive risk factors. Our finding will be helpful in the selection of a future treatment approach.

MATERIALS AND METHODS {#s4}
=====================

We retrospectively analyzed 234 consecutively treated patients who had received molecular targeted drugs for mRCC. According to the therapeutic strategy in our institute, sorafenib was used as the first-line therapy and sunitinib or everolimus as the second-line therapy. However, since 2010, sunitinib has become the first-line therapy, and since 2012, axitinib has become the second-line therapy. We calculated OS and OS classified according to the MSKCC criteria. The OS period commenced from the time of treatment with the initial targeted therapy.

Next, we examined the difference between PFS and OS among patients in the intermediate-risk group of the MSKCC criteria. We divided the intermediate group into two subgroups as follows: patients who were positive for only one risk factor (Int-1) and those who were positive for two risk factors (Int-2) including performance status (PS), serum hemoglobin level, time from diagnosis to treatment, and corrected calcium and lactate dehydrogenase (LDH) levels. Subsequently, we investigated which factors had an influence on OS between the Int-1 and Int-2 groups.

OS was estimated using the Kaplan-Meier method and the differences were determined using the log-rank test. Cox proportional stepwise multivariate analysis was used to evaluate the association between the number of metastatic organs, Int-1 or 2 grouping, presence or absence of pancreatic metastasis, and OS. A p-value \<0.05 was considered statistically significant. All statistical analyses were performed using Microsoft Excel^®^ (Microsoft, Redmond, Washington, USA). Permission to access the database for a review of the medical records of these patients was obtained from the local research ethics committee at Osaka City University (approval number 3441).

SUPPLEMENTARY MATERIALS FIGURES {#s5}
===============================
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